EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how

Giulia Maneri iD, Camilla Nero iD, Luciano Giacò iD, Giovanni Scambia iD, Angelo Minucci iD

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Giulia Maneri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Germ-Line Mutation, Genetic Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of tumor comprehensive genomic profiling (CGP) currently does not include a matched normal control. The use of a tumor-only CGP approach needs the development of a strategy to refine germline pathogenic/likely pathogenic variants (gP/LPVs) calls, so as to limit the performance of unnecessary germline reflex tests and instead successfully identify patients who are carriers of likely gP/LPVs. Guidelines have been developed for the identification of gP/LPVs in BRCA1/2 genes on the basis of tumor-only CGP results and for the evaluation of the appropriateness of performing germline reflex BRCA1/2 testing. In this study, an algorithm to assist decision-making for germline reflex testing of BRCA1/2 variants following tumor-only CGP is proposed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationGenetic TestingHumansFemaleAlgorithmsBreast NeoplasmsBRCA2 ProteinBRCA1 ProteinGenes, BRCA2Genes, BRCA1Ovarian NeoplasmsGenetic Predisposition to DiseaseGenomics

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Genomics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Scientific Directorate, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
  • Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Bioinformatics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Scientific Directorate, Policlinico Gemelli IRCCS Foundation, Rome, Italy.
  • Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.

ORCID-Profile: Giulia Maneri, Camilla Nero, Luciano Giacò, Giovanni Scambia, Angelo Minucci

Zitieren

APA

Maneri, G., Nero, C., Giacò, L., Scambia, G., & Minucci, A. (2024). Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae096

Vancouver

Maneri G, Nero C, Giacò L, Scambia G, Minucci A. Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae096

BibTeX
@article{Maneri2024,
  author = {Maneri, Giulia and Nero, Camilla and Giacò, Luciano and Scambia, Giovanni and Minucci, Angelo},
  title = {Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae096}
}
Kostenlos starten →